Extended access study for patients benefiting from DS drugs
Treatments studied
Part of Cancer clinical trials.
This study allows people who are already in a Daiichi Sankyo trial and getting benefit from the study drug to continue receiving it safely. It monitors long-term safety for those who have not had their cancer worsen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be currently enrolled in a Daiichi Sankyo or AstraZeneca trial that has completed its main follow-up period.
- You must not have signs that your disease is getting worse, and your doctor must believe you are still benefiting from the study drug.
- You must not have any side effects from the drug that would normally cause it to be stopped.
- You must not have had a break from the drug longer than 18 weeks since your last dose in the parent study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well Trastuzumab Deruxtecan (T-DXd) works in Chinese women with breast cancer that has spread. It is for people whose cancer is either HER2-positive or HER2-low and who have already had some treatment.
This study is testing a drug called T-DXd (a targeted therapy) in people with advanced breast cancer that has HER2 overexpression or underexpression. It looks at how well the drug works in real-world settings, which may provide a new treatment option if your cancer has progressed.
This trial tests a new combination treatment for people with advanced solid tumors that have HER2 changes. The goal is to see if it can shrink tumors or slow growth.
This study checks whether continuing ASTX727 for people who already benefited from it in an earlier Taiho study is safe and effective. It may be an option if you stayed on ASTX727 at the end of your parent study and your doctor felt it was helping you.
This study looks at people with advanced breast cancer who will receive a drug called T-DXd. Researchers want to understand the side effects of this treatment by analyzing blood samples.
This trial tests a new drug called DS3610a for people with advanced solid tumors that have stopped responding to other treatments. You may be able to join if you have tried standard therapies and are willing to provide a tumor sample.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.